The trial demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate ...

Calcium-containing phosphate binders are the current mainstay of treatment for hyperphosphatemia in children with chronic kidney disease (CKD), but they are associated with an increased risk of ...

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require ...

The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%. Iron-based phosphate binder is expected to grab 20% of the hyperphosphatemia market by ...

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics, Inc., Vifor Pharma Management Ltd., Lupin ...

Hyperphosphatemia is very common in people with chronic kidney disease more often in people with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes diabetic ...

Red meat, long acclaimed for its richness in protein, iron and vitamin B12, is now at the heart of numerous debates concerning its effects on health. A Scottish study published in the journal Aging ...

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd. , Lupin Limited, ...

WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...